AstraZeneca, Merck Get CHMP Positive Opinion for Lynparza in Pancreatic Cancer
June 01 2020 - 10:15AM
Dow Jones News
By Colin Kellaher
AstraZeneca PLC and Merck & Co. Monday said the European
Medicines Agency's Committee for Medicinal Products for Human Use
recommended approval of the cancer drug Lynparza in a form of
pancreatic cancer.
The drugmakers said the recommendation covers Lynparza as
monotherapy for the maintenance treatment of adults with germline
BRCA1/2 mutations who have metastatic adenocarcinoma of the
pancreas and haven't progressed after a minimum of 16 weeks of
platinum treatment within a first-line chemotherapy regimen.
The indication now awaits approval from the European Commission,
which generally follows the CHMP's recommendations.
AstraZeneca and Merck in 2017 formed a collaboration to
co-develop and co-commercialize Lynparza for multiple cancer
types.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 01, 2020 11:00 ET (15:00 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.